Durability of Response in Plaque Psoriasis Patients Receiving Certolizumab Pegol Over 48 Weeks in Phase 3 Studies: CIMPASI-1, CIMPASI-2, CIMPACT
Author Type(s)
Faculty
Document Type
Abstract
Publication Date
5-2019
Journal Title
Australasian Journal of Dermatology
Department
Dermatology
Recommended Citation
Augustin, M., Weglowska, J., Lebwohl, M., Paul, C., Piguet, V., Sofen, H., Blauvelt, A., Peterson, L., Rolleri, R., Reich, K., Thaci, D., Leonardi, C., Poulin, Y., Arendt, C., & Gottlieb, A. (2019). Durability of Response in Plaque Psoriasis Patients Receiving Certolizumab Pegol Over 48 Weeks in Phase 3 Studies: CIMPASI-1, CIMPASI-2, CIMPACT. Australasian Journal of Dermatology, 60 (Suppl. 1), 14-15. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/292
COinS
